Abstract: A pharmaceutical composition is described. The composition may include a drug component and a propellant component. The drug component comprises at least one pharmaceutically acceptable salt of glycopyrrolate and at least one long acting beta-2-agonist (LABA) selected from formoterol and the pharmaceutically acceptable salts thereof. At least 90 weight % of the propellant component is 1,1-difluoroethane (HFA-152a).

Abstract: A process for reducing the concentration of one or more arsenic-containing compounds in an aqueous solution comprising at least one fluoroacid, which process comprises: (i) contacting the aqueous solution with an oxidising agent to produce one or more Asv-containing compounds; and (ii) removal of precipitated arsenic-containing compounds; wherein the process comprises a step (iii) the addition of an aqueous alkali solution or slurry, which may take place after step (i) and before step (ii) or after step (ii).

Abstract: The present invention relates to compounds according to formula (Ia) or formula (Ib); wherein each W is independently selected from the group consisting of H, F, Cl, Br, I and (CY2)mCY3; each Y is independently selected from the group consisting of F, Cl, Br and I; each Z is independently selected from the group consisting of H, OH, (CW2)pCW3, CY3, OCW3, O(CW2)pCW3, OCW((CY2)mCY3)CWCW2, (CW2)pOH, polyalkylene glycol and polyolester; n is an integer from 2 to 49; m is an integer from 0 to 3; p is an integer from 0 to 9; the molecular weight average (MW) is ?5500; and the polydispersity index is ?1.45; compositions comprising these compounds and methods for their production.

Abstract: A pharmaceutical composition is described. The chemically stable pharmaceutical composition comprises a drug component. The drug component consists of a) mometasone, mometasone furoate, or a combination thereof; and b) formoterol fumarate dihydrate. The chemically stable pharmaceutical composition also comprises a propellant component comprising at least 90 weight % 1,1-difluoroethane; and ethanol in an amount of from 0.5 to 10% by weight based on the total weight of the chemically stable pharmaceutical composition. The drug component comprises from 0.01 to 1.0 weight % of the total weight of the chemically stable pharmaceutical composition. The drug component is the sole drug component in the chemically stable pharmaceutical composition. The chemically stable pharmaceutical composition is in the form of a suspension and free of acid stabilizers. The chemically stable pharmaceutical composition is surfactant-free.

Abstract: The present invention provides a process for preparing 1,1,1,2,2-pentafluoropropane (245cb), the process comprising gas phase catalytic dehydrochlorination of a composition comprising 1,1,1-trifluoro-2,3-dichloropropane (243db) to produce an intermediate composition comprising 3,3,3-trifluoro-2-chloro-prop-1-ene (CF3CCI?CH2, 1233xf), hydrogen chloride (HCl) and, optionally, air; and gas phase catalytic fluorination with hydrogen fluoride (HF) of the intermediate composition to produce a reactor product composition comprising 245cb, HF, HCl and air; wherein the process is carried out with a co-feed of air.

Abstract: A pharmaceutical composition is described. The chemically stable pharmaceutical composition comprises (i) a drug component consisting of mometasone, mometasone furoate, or a combination thereof, (ii) a propellant component comprising 1,1-difluoroethane (R-152a), and (iii) ethanol in an amount of from 0.5 to 10% by weight based on the total weight of the chemically stable pharmaceutical composition. The drug component comprises from 0.01 to 1.0 weight % of the total weight of the chemically stable pharmaceutical composition. At least 95 weight % of the propellant component is 1,1-difluoroethane (R-152a). The drug component is the sole drug component in the pharmaceutical composition. The chemically stable pharmaceutical composition is surfactant-free.

Abstract: The present invention provides a composition, such as a refrigerant composition comprising 1,1-difluoroethene (vinylidene fluoride, R-1132a); trifluoromethane (R-23); and one or more compound selected from hexafluoroethane (R-116), ethane (R-170) and carbon dioxide (R-744, CO2).

Abstract: A pharmaceutical composition is described. The composition comprises: (i) at least one formoterol compound selected from formoterol, pharmaceutically acceptable salts of formoterol, prodrugs of formoterol, solvates of formoterol, solvates of pharmaceutically acceptable salts of formoterol and solvates of prodrugs of formoterol; (ii) at least one corticosteroid; (iii) a surfactant component comprising at least one surfactant compound; and (iv) a propellant component comprising 1,1-difluoroethane (R-152a).

Abstract: A pharmaceutical composition is described. The composition comprises: (i) at least one formoterol compound selected from formoterol, pharmaceutically acceptable salts of formoterol, prodrugs of formoterol, solvates of formoterol, solvates of pharmaceutically acceptable salts of formoterol and solvates of prodrugs of formoterol; (ii) at least one corticosteroid; (iii) a surfactant component comprising at least one surfactant compound; and (iv) a propellant component comprising 1,1-difluoroethane (R-152a).

Abstract: A pharmaceutical composition is described. The composition comprises: (i) at least one formoterol compound selected from formoterol, pharmaceutically acceptable salts of formoterol, prodrugs of formoterol, solvates of formoterol, solvates of pharmaceutically acceptable salts of formoterol and solvates of prodrugs of formoterol; (ii) at least one corticosteroid; (iii) a surfactant component comprising at least one surfactant compound; and (iv) a propellant component comprising 1,1-difluoroethane (R-152a).

Abstract: In the field of medical dosing device filling, a propellant conditioning assembly (10) comprises an input conduit (12) to receive a propellant at a constant pressure from a propellant reservoir (102). The conditioning assembly (10) also includes a bifurcation (18) to divide the input conduit (12) into first and second conditioning conduits (20, 22). The first conditioning conduit (20) includes a cooler device (24) to selectively cool a diverted first propellant stream (26) that flows through the first conditioning conduit (20), and the second conditioning conduit (22) includes a heater device (32) to selectively heat a diverted second propellant stream (34) that flows through the second conditioning conduit (22). The conditioning assembly (10) still further includes an output conduit (44) to receive the first and second propellant streams (26, 34).

Abstract: A catalyst comprising one or more metal oxides, wherein the catalyst has a total pore volume equal to or greater than 0.3 cm3/g and a mean pore diameter greater than or equal to 90 ?, where in the pore volume is measured using N2 adsorption porosimetry and the mean pore diameter is measured using N2 BET adsorption porosimetry.

Abstract: A composition comprising: (i) 1,1-difluoroethene (vinylidene fluoride, R-1132a); (ii) carbon dioxide (CO2, R-744); (iii) pentafluoroethane (R-125); and (iv) one or more of trifluoromethane (R-23) and hexafluoroethane (R-116).

Abstract: A method for preparing a tetrafluoro-1,2-epoxypropane comprising reacting a 3-acetoxy-2-bromo-tetrafluoropropane with an alkaline or alkaline earth metal hydroxide solution to provide a tetrafluoro-1,2-epoxypropane, and partially fluorinated polyethers of formula [OCRR1CR2R3]n wherein n is from 5 to 100, R is F or H, R1 is CF3, R2 is F or H and R3 is H.

Abstract: A catalyst comprising chromia and at least one additional metal or compound thereof and wherein the catalyst has a total pore volume of greater than 0.3 cm3/g and the mean pore diameter is greater than or equal to 90 ?, wherein the total pore volume is measured by N2 adsorption porosimetry and the mean pore diameter is measured by N2 BET adsorption porosimetry, and wherein the at least one additional metal is selected from Li, Na, K, Ca, Mg, Cs, Sc, Al, Y, Ti, Zr, Hf, V, Nb, Ta, Cr, Mo, W, Mn, Re, Fe, Ru, Co, Rh, Ir, Ni, Pd, In, Pt, Cu, Ag, Au, Zn, La, Ce and mixtures thereof.

Abstract: A method for preparing atetrafluoro-1,2-epoxypropane comprising reacting a 2-bromo-tetrafluoropropan-3-ol with an alkaline or alkaline earth metal hydroxide solution, a compound which is 2,3,3,3-tetrafluoro-1,2-epoxypropane, and partially fluorinated polyethers of formula [OCRR1CR2R3]n wherein n is from 5 to 100, R is F or H, R1 is CF3, R2 is F or H and R3 is H.

Abstract: A pharmaceutical composition is described. The composition comprises: (i) a drug component consisting of salmeterol xinafoate and fluticasone propionate. and (ii) a propellant component at least 90 wt % of which is 1,1-difluoroethane (HFA-152a). The drug component is the sole drug component in the pharmaceutical composition.

Abstract: The invention relates to a process comprising contacting a composition comprising a (hydro)halocarbon and a compound of formula Rf—C?CX with a basic solution comprising an hydroxide, an alkoxide and/or an amide to reduce the concentration of Rf—C?CX, wherein Rf is a perfluorinated alkyl group and X is H, F, Cl, Br, or I. The invention further relates to process for preparing a (hydro)halocarbon comprising (i) converting a starting material, optionally in the presence of HF and/or a catalyst, to a composition comprising the (hydro)halocarbon and a compound of formula Rf—C?CX, wherein Rf is a perfluorinated alkyl group and X is H, F, Cl, Br, or I; (ii) contacting the composition with a basic solution comprising an hydroxide, an alkoxide and/or an amide to reduce the concentration of the compound of formula Rf—C?CX; and (iii) recovering the (hydro)halocarbon.

Abstract: A pharmaceutical composition is described. The composition comprises: (i) a drug component comprising at least one salmeterol compound selected from salmeterol and the pharmaceutically acceptable derivatives thereof; and (ii) a propellant component comprising 1,1-difluoroethane (HFA-152a).

Abstract: The present invention provides a process for preparing 1,1,1,2,2-pentafluoropropane (245cb), the process comprising gas phase catalytic dehydrochlorination of a composition comprising 1,1,1-trifluoro-2,3-dichloropropane (243db) to produce an intermediate composition comprising 3,3,3-trifluoro-2-chloro-prop-1-ene (CF3CCI?CH2, 1233xf), hydrogen chloride (HCl) and, optionally, air; and gas phase catalytic fluorination with hydrogen fluoride (HF) of the intermediate composition to produce a reactor product composition comprising 245cb, HF, HCl and air; wherein the process is carried out with a co-feed of air.